Lv41
523 积分 2022-05-29 加入
Enhanced artemisin optimization and kernel extreme learning machine for identifying key features in predicting patient mortality due to ST-elevation myocardial infarction
1小时前
求助中
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
1天前
待确认
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
2天前
已完结
Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease
4天前
已完结
A hierarchized proposal to integrate steatotic liver disease in cardiometabolic care: A new mindset to evaluate MASLD in Internal medicine
4天前
求助中
Target Populations for Novel Triglyceride-Lowering Therapies
4天前
已完结
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
4天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
4天前
已完结
Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
4天前
已完结
BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†
4天前
已完结
皖公网安备34019202002308
